Pacira发布美国劳动力疼痛负担调查，未披露产品获批、订单或业绩增量

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
Content Import
July 28, 2026

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

July 28, 2026

General

- Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options -
BRISBANE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from the Standing Strong: The Impact of Pain on America's Workforce survey, which explored how orthopedic pain affects adults working in physically demanding occupations such as first responders, active military, retail workers, teachers, and tradespeople.
The findings presented are based on a survey of 1,000 U.S. adults employed full-time in occupations that require them to spend at least some of their workday on their feet. Results reflect the experiences and opinions of survey respondents and are not intended to be representative of all U.S. workers or to support broader population-level conclusions.
Respondents were asked about orthopedic pain related to movement or strain in the knees, back, feet, joints, or muscles. Among those surveyed, 85% reported experiencing pain at least sometimes while working, including 41% who reported experiencing pain often or all the time.
Key survey findings highlighted the widespread impact of pain on America's workforce, including reported effects on income, career advancement, and quality of life.
Real Consequences for Income, Careers and Daily Life
The survey findings suggest that pain may affect workers both on and off the job. More than half of workers surveyed (54%) reported losing income because of pain-related missed shifts or reduced hours, while 46% said pain had prevented them from pursuing opportunities that could have advanced their careers or increased their income. More than half (55%) said they would choose a less physically demanding career if given the chance, rising to 73% among active military respondents.
At the same time, many workers reported managing pain without seeking support. Eighty-one percent reported having experienced pain at work without telling a supervisor, manager, or colleague, while nearly 90% said they typically push through pain rather than ask for help.
Knee Pain Emerges as a Leading Concern
Among workers experiencing pain, knee pain emerged as the most commonly reported complaint, affecting nearly three-quarters of respondents. More than half of all respondents (56%) reported chronic knee pain, meaning their symptoms had persisted for three months or longer.
The impact appears to extend beyond the workplace. Within respondents reporting knee pain as their primary pain concern, 66% said pain negatively affects their social lives and personal relationships, underscoring the broader quality-of-life burden associated with persistent pain.
While the survey did not assess whether participants had been diagnosed with knee osteoarthritis (OA), OA is the most common cause of chronic knee pain, affecting nearly 15 million Americans. As a progressive joint disease, knee OA becomes more common with age, and among survey respondents aged 45 years and older, 28% reported chronic knee pain. Knee OA can significantly impact mobility, physical function and overall quality of life.
Interest in Long-Lasting, Non-Opioid Pain Management Options
Among respondents reporting chronic knee pain, the survey identified a meaningful gap between current pain-management approaches and treatment preferences. While 24% reported using prescription opioids, nearly all (98%) said they would consider a long-lasting, non-opioid treatment option if it provided meaningful relief. This disconnect suggests that many workers may be relying on short-term or higher-risk options, even as they express strong interest in safe, long-lasting alternatives.
As awareness of non-opioid pain management approaches continues to grow, healthcare providers are increasingly focused on providing treatments that can help appropriate patients maintain mobility and function.
Expert Perspective: Treating Knee Pain in Practice
“Work-related pain often starts as something patients try to manage on their own, but when knee pain becomes chronic, most commonly due to osteoarthritis (OA), it can significantly impact mobility, function, and overall quality of life,” said Dr. Anthony Boniello, orthopaedic surgeon at Princeton Orthopaedic Associates and spokesperson for the Standing Strong initiative. “In my practice, we focus on individualized care that may include non-opioid treatment options such as physical therapy and intra-articular injections. ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension) is one option I use for appropriate patients to help provide extended relief from OA knee pain. The goal is to help patients stay active and maintain function.”
Addressing a Workforce Issue, Not Just a Medical One
“These findings suggest that many workers have come to view pain as simply part of the job, even when it affects their work, mobility, and quality of life,” said Brendan Teehan, Chief Commercial Officer at Pacira BioSciences . “Pain may be part of the job today, but it doesn’t have to define the future of America’s workforce. Increasing awareness and encouraging conversations between patients and healthcare providers are important steps in helping people understand that better is possible, and that effective, non-opioid treatment options may help them manage pain, improve function, and get back to the activities that matter most.”
About Standing Strong
Standing Strong: The Impact of Pain on America’s Workforce is a national initiative designed to spotlight the everyday impact of pain on America’s workforce, particularly those in physically demanding roles.
The findings are based on a survey commissioned by Pacira BioSciences, Inc. and conducted by Wakefield Research among 1,000 U.S. adults employed full-time and working on their feet at least some of the time, including first responders, food service and hospitality workers, teachers, retail workers, tradespeople/laborers, and active military personnel. The survey was conducted online between April 17 and May 3, 2026. To download a survey report and infographic with additional survey findings, visit https://www.pacira.com/patients/insights/standing-strong/ .
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.
Indication and Important Risk Information
About ZILRETTA?
ZILRETTA ®  (triamcinolone acetonide extended-release injectable suspension) is an extended-release corticosteroid approved to manage osteoar